Montelukast nanoparticle - PharmaKing

Drug Profile

Montelukast nanoparticle - PharmaKing

Alternative Names: MKT-N2; PMK-M01RS1

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator PharmaKing
  • Class Acetates; Antiasthmatics; Quinolines; Small molecules
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Asthma
  • Discontinued Allergic rhinitis

Most Recent Events

  • 17 May 2016 Chemical structure information added
  • 12 May 2016 Discontinued - Phase-I for Allergic rhinitis (In volunteers) in South Korea (PO)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top